What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 24 months?
One-OffSalute e medicinaScienza1m
Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoAvviso sulla qualità dei datiDati della fonte degradati
Dati al 25 ott 2026, 18:45 UTC · criterio pm-quality-4
Previsione della comunità attuale70-79% 38.7%In testa tra 7 esiti
Previsori
14
Tipo di domanda
multiple choice
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Variazione 7g
+16.9 pts
Dati di mercato
Aggiornato 12 ore fa
Obsoleto15 mar 24, 21:17 UTC2 dic 26, 07:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill molecular jackhammers have at least 50% tumour-free efficacy in Phase 2 clinical trials?
Manifold MarketsHow many tuberculosis cases will be reported in the United States in 2026?
KalshiHow many human H5N1 cases will be reported in the United States in 2026?
KalshiHow many gonorrhea cases will be reported in the United States in 2026?
KalshiHow many human screwworm cases will be reported in the United States in 2026?
KalshiRegole
The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.
- Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
- Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2025).
- Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
- 1Day Sooner has an R21 Status Report available here that may be useful.
- More malaria-related questions can be found on our Manifold account here.
